Document Classification

Section Type: OBJECTIVE

Text: The immunogenicity and safety of a new liquid hexavalent vaccine (diphtheria-tetanus-acellular pertussis-inactivated polio vaccine-hepatitis B-polyribosyl ribitol phosphate conjugated to tetanus protein ; Hexavac ; Aventis Pasteur MSD, Lyon, France) are compared with those of reference vaccines [diphtheria-tetanus-acellular pertussis-inactivated polio vaccine reconstituting lyophilized purified Haemophilus influenzae polysaccharide conjugated to tetanus protein vaccine (Pentavac ; Aventis Pasteur MSD) and hepatitis B vaccine (H-B-Vax II ; Aventis Pasteur MSD)] injected separately at the same visit in a prospective multicenter, comparative, open label trial.